130 related articles for article (PubMed ID: 22493624)
1. Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected].
Di Bonito M; Collina F; Cantile M; Camerlingo R; Cerrone M; Marra L; Liguori G; Pirozzi G; Botti G
J Breast Cancer; 2012 Mar; 15(1):15-23. PubMed ID: 22493624
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of CD133
Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment detection of circulating and tissue CD133
Zahran AM; Rayan A; Fakhry H; Attia AM; Ashmawy AM; Soliman A; Elkady A; Hetta HF
Cancer Manag Res; 2019; 11():1237-1248. PubMed ID: 30799951
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.
Han Z; Chen Z; Zheng R; Cheng Z; Gong X; Wang D
World J Surg Oncol; 2015 Feb; 13():56. PubMed ID: 25889325
[TBL] [Abstract][Full Text] [Related]
7. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
8. The Pinx1 Gene Downregulates Telomerase and Inhibits Proliferation of CD133+ Cancer Stem Cells Isolated from a Nasopharyngeal Carcinoma Cell Line by Regulating Trfs and Mad1/C-Myc/p53 Pathways.
Shen C; Chen F; Wang H; Li G; Yu C; Wang X; Wen Z
Cell Physiol Biochem; 2018; 49(1):282-294. PubMed ID: 30138944
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
10. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
11. Detection of putative stem cell markers, CD44/CD133, in primary and lymph node metastases in head and neck squamous cell carcinomas. A preliminary immunohistochemical and in vitro study.
Mannelli G; Magnelli L; Deganello A; Busoni M; Meccariello G; Parrinello G; Gallo O
Clin Otolaryngol; 2015 Aug; 40(4):312-20. PubMed ID: 25641707
[TBL] [Abstract][Full Text] [Related]
12. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer.
Pirozzi G; Tirino V; Camerlingo R; La Rocca A; Martucci N; Scognamiglio G; Franco R; Cantile M; Normanno N; Rocco G
Oncol Rep; 2013 May; 29(5):1763-8. PubMed ID: 23426441
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
Zhao P; Lu Y; Jiang X; Li X
Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
17. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
18. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
[TBL] [Abstract][Full Text] [Related]
19. Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays.
Nie S; Gurrea M; Zhu J; Thakolwiboon S; Heth JA; Muraszko KM; Fan X; Lubman DM
J Proteome Res; 2015 Feb; 14(2):814-22. PubMed ID: 25469866
[TBL] [Abstract][Full Text] [Related]
20. Incomplete radiofrequency ablation promotes the development of CD133
Yuan CW; Wang ZC; Liu K; Liu DJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):416-422. PubMed ID: 30262419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]